SeaBeLife Biotech

SeaBeLife pioneers a revolutionary therapeutic paradigm aimed at halving the medical burden, including mortality rates, of severe pathologies lacking effective treatments. Our strategy focuses on developing First-In-Class small Drugs, rooted in a proprietary platform technology comprising small molecules that halt cellular death and forestall organ failure. With a robust pipeline boasting 150 patented molecules exclusively licensed to SeaBeLife, our innovative approach targets critical medical needs. Currently, we are advancing two assets through preclinical development: SBL01, designed to address life-threatening Orphan and Acute Liver Injuries / Failures (ALI/ALF), and SBL03, aiming to preserve vision in Dry-AMD patients, a leading cause of blindness globally among the elderly. These initiatives promise to transform patient outcomes, addressing significant social, economic, and healthcare challenges.